Added to YB: 2026-09-04
Pitch date: 2026-09-02
COV.V [neutral]
Covalon Technologies Ltd.
+2.69%
current return
Author Info
Stocks & Stones manages the Rivemont MicroCap Fund, which has several million $ in assets. I’m here to help you avoid the pitfalls of microcap investing. Sign up for the newsletter.
Company Info
Covalon Technologies Ltd. engages in the research, development, manufacturing, and marketing of medical products in infection management, advanced wound care, and surgical procedure areas in the United States, the Middle East, Canada, Latin America, Asia, and internationally.
Market Cap
CAD 82.9M
Pitch Price
CAD 2.97
Price Target
N/A
Dividend
N/A
EV/EBITDA
14.61
P/E
18.84
EV/Sales
1.90
Sector
Biotechnology
Category
N/A
The Good, the Bad, and the Ugly (August 2026) - Covalon Technologies Ltd.
COV.V (earnings): Covalon Technologies arguably delivered its best quarter ever: revenue reached $10 million, the second-highest level in company history behind an outlier in 2019, while operating income set a record at $2.7 million for a 27% margin. Quarterly EPS of $0.10 exceeded the prior five quarters combined, and the shares rose 35% in the days following the release.
Read full article (1 min)